Synaptogenix Inc: Rises after panel confirms safety of Alzheimer's drug

TAO Synergies

09/06/2021 15:17

** Drug developer's shares  SNPX.O  rise 2% to $7.14
    ** Company says independent safety monitoring panel
overseeing mid-stage trial of SNPX's lead candidate,
Bryostatin-1, for Alzheimer's disease confirmed 40 patients
affected by the disease have been dosed with the drug without
any significant safety issues  urn:newsml:reuters.com:*:nPndJGWva
    ** SNPX says it has now dosed 58 of its target 100 patients
    ** U.S. FDA on Monday in a landmark decision approved Biogen
Inc's  BIIB.O  drug Aduhelm as the first treatment to target a
likely underlying cause of Alzheimer's disease  urn:newsml:reuters.com:*:nL2N2NP12J
    ** BIIB shares closed up 38.3% on Monday
    ** Shares of other Alzheimer's drug developers Eli Lilly
 LLY.N , Axsome Therapeutics  AXSM.O , AC Immune  ACIU.O ,
Anavex Life Sciences  AVXL.O  also gained on Monday

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com))